Hospital Universitario Doctor Peset -ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2019

  1. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

    Haematologica, Vol. 104, Núm. 11, pp. 2249-2257

2017

  1. Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload

    Clinical Biochemistry, Vol. 50, Núm. 16-17, pp. 911-917

2013

  1. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

    Blood, Vol. 122, Núm. 24, pp. 3951-3959

2008

  1. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

    Haematologica, Vol. 93, Núm. 7, pp. 1001-1008